AVM Biotechnology
Share
Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from AVM Biotechnology, Biotechnology company, 1749 Dexter Avenue N, Seattle, WA.
Transforming the future of immunotherapy with AVM0703, our innovative drug which mobilizes the body's own immune system to potentially fight cancer, infectious disease, and autoimmune disorders.
AVM Biotechnology:
a National Institute of Health 2024 Innovation Company; National Cancer Institute 2023 Showcase Company; NIH/NIDDK 2022 Showcase Company
01/05/2023
AVM was highlighted as a Company to Watch in 2023 by Life Science Nation.
Companies to Watch 2023 By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series For the past ten years, Life Science Nation (LSN) has built a global partnering platform that matches s…
08/25/2022
AVM was recently awarded a Ph I SBIR Grant from the National Cancer Institute to study AVM0703 in conjunction with standard of care, R-CHOP, in Non-Hodgkin's Lymphoma to improve complete response rates without further toxicities. This is the company's third Ph I SBIR grant. AVM0703 has the potential to become an important treatment modality for NHL patients solidifying AVM’s influence in the immunotherapy space.
https://www.businesswire.com/news/home/20220825005287/en/NIH-Awards-AVM-Biotechnology-SBIR-Grant-to-Study-AVM0703-Combined-with-Standard-of-Care-in-Non-Hodgkin%E2%80%99s-Lymphoma-NHL-to-Improve-Complete-Response-Rates-Without-Additional-Toxicities
06/14/2022
AVM Biotechnology has received a $2 M Phase II SBIR grant from the National Cancer Institute to further the company’s clinical trial treating R/R NHL/Leukemia. This is additional validation of the important work we are doing developing AVM0703 for the treatment of cancer.
https://www.businesswire.com/news/home/20220614005414/en/AVM-Biotechnology-Awarded-2-Million-National-Cancer-Institute-SBIR-Phase-II-Grant-from-the-National-Institutes-of-Health-to-Advance-AVM0703-in-Cancer
06/01/2022
AVM Founder and CSO, Dr. Theresa Deisher, to Present Poster Highlighting the Effects of AVM0703 Against Solid Tumors and Blood Cancers at the 2022 ASCO Annual Meeting in Chicago.
See the full press release here:
https://www.businesswire.com/news/home/20220601005424/en/AVM-Biotechnology-to-Present-Poster-Highlighting-the-Effects-of-AVM0703-Against-Solid-Tumors-and-Blood-Cancers-at-the-2022-ASCO-Annual-Meeting
04/21/2022
We were thrilled to participate in person at Life Science Innovation Northwest where Dr. Deisher presented to a standing room only crowd, we were able to speak with potential investors and partners, and were honored with a 2nd place award for our poster describing the potential of AVM0703.
04/19/2022
AVM Founder and CSO, Dr. Theresa Deisher, to provide invited company and poster presentations at Life Science Innovation Northwest on April 20th. https://www.businesswire.com/news/home/20220419005486/en
Click here to claim your Sponsored Listing.
Category
Contact the business
Telephone
Website
Address
1749 Dexter Avenue N
Seattle, WA
98109